Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024
Period Ending	Mar 31, 2025	Dec 31, 2024
Cash & Equivalents	83.57	61.58
Short-Term Investments	265.52	314.07
Cash & Short-Term Investments	349.09	375.65
Prepaid Expenses	2.99	1.22
Total Current Assets	352.08	376.87
Property, Plant & Equipment	0.97	1.04
Long-Term Investments	23.95	18.07
Other Long-Term Assets	0.1	0.04
Total Assets	377.11	396.02
Accounts Payable	3.55	3.46
Accrued Expenses	6.48	9.37
Current Portion of Leases	0.28	0.21
Total Current Liabilities	11.72	13.04
Long-Term Leases	0.66	0.76
Total Liabilities	12.39	13.8
Common Stock	0.04	0.04
Additional Paid-In Capital	466.49	463.02
Retained Earnings	-104.72	-83.72
Comprehensive Income & Other	-0.01	-0.04
Total Common Equity	361.79	379.29
Shareholders' Equity	364.73	382.22
Total Liabilities & Equity	377.11	396.02
Total Debt	0.95	0.97
Net Cash (Debt)	372.1	392.75
Net Cash Per Share	14.09	23.39
Filing Date Shares Outstanding	37.44	37.44
Total Common Shares Outstanding	37.44	37.44
Working Capital	340.36	363.83
Book Value Per Share	9.66	10.13
Tangible Book Value	361.79	379.29
Tangible Book Value Per Share	9.66	10.13

Updated Mar 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q